Unveiling the Transformative Developments in the Pharmaceutical Investment Landscape During the Chinese New Year Holiday

As the Chinese New Year holiday unfolded, significant developments took place in the realm of pharmaceutical investments. Despite experiencing extreme market conditions, investors should remain confident, particularly those involved in the healthcare and pharmaceutical sectors. The pharmaceutical industry has thrived through successive cycles of capital accumulation, and at this pivotal historical moment, it is crucial for pharmaceutical investors to approach the current market conditions with rationality. Let's delve into the major investment events that occurred in the pharmaceutical industry during the Chinese New Year holiday.

1. Blossoming of the "Freedom Flower":

The pricing of innovative drugs has always been a focal point for pharmaceutical investors in China. On February 5th, the National Medical Insurance Administration issued a draft for soliciting opinions titled "Notice on Establishing the Mechanism for Pricing New Listed Chemical Drugs to Encourage High-Quality Innovation." This draft opens up the opportunity for independent pricing of innovative drugs and encourages the development of China's pharmaceutical industry. For the Chinese pharmaceutical industry, this is undoubtedly a significant positive development. Pharmaceutical companies will be able to make more objective and fair judgments on newly listed drugs through independent quantitative evaluations. The highest score a new drug can receive is 150 points, with drugs scoring between 90 and 150 points receiving maximum policy support in terms of pricing. Drugs scoring between 50 and 90 points will accept the independent pricing results, but transparency and fairness of the initial pricing will also be taken into consideration. Drugs scoring below 50 points will not have high pricing expectations. Within this scoring system, new mechanisms, new targets, and breakthrough therapies will receive higher score bonuses. As more drugs of the same kind are introduced, the scoring points for drugs will gradually decrease. In essence, drugs with higher self-assessment scores will have greater innovation content and more pricing flexibility after market launch. This new evaluation system redirects the core focus of pharmaceutical investments back to fundamental innovation capabilities. Pharmaceutical companies' reliance on marketing tactics will significantly diminish, while enterprises focusing on cutting-edge innovation and filling gaps in domestic healthcare will emerge as the major beneficiaries.

2. Tumbling of the Pharmaron Group:

During the Chinese New Year holiday, three Hong Kong-listed companies affiliated with the Pharmaron Group experienced substantial declines in their stock prices. Comparing the closing stock prices on February 7th and February 16th, Pharmaron Kantor, Pharmaron Biotech, and Pharmaron Alliance witnessed declines of 20.7%, 9.9%, and 19.2%, respectively. Analyzing these three companies, there is no apparent substantial negative news. The core reason for such significant declines lies in weakened investor confidence and heightened industry uncertainties. As the CXO industry primarily engages in global business, its future development hinges on the ability to sustain overseas orders. The complex international landscape has intensified investors' concerns about future orders in the CXO industry, leading to stock sell-offs at the slightest market turbulence. Although irrational, such sell-offs are not uncommon in the market. Besides the fundamental factors, frequent asset splits and share reductions within the Pharmaron Group have fostered discontent among investors, exacerbating stock volatility during downturns. The long-term investors, who determine a company's stock price trend, ensure a lower valuation limit for the company's assets. If a company lacks long-term investors and primarily attracts speculative traders, stock price fluctuations will be more severe, as these traders do not prioritize asset value but instead focus on whether the stock price will continue to decline. The Pharmaron Group serves as a typical case in pharmaceutical investments, where even loyal long-term investors find it challenging to accept frequent capital operations by the company.

3. Pharmaceutical Companies Embrace Buybacks:

How can a company swiftly emerge from the capital winter? It depends on its ability to cultivate a loyal base of long-term investors. For pharmaceutical companies currently navigating the capital winter, demonstrating management's commitment is best achieved by repurchasing undervalued shares from the market. Such buybacks signify the management's stance toward undervalued stock prices and also indicate the company's healthy cash flow, which is crucial for pharmaceutical companies during the winter season. Incomplete statistics reveal that Pharmaron Biotech, Genscript Pharmaceutical, Nuocheng Jianhua, Lijun Pharmaceutical, Weitai Medical, Rui'er Group, Meiyin Genetics, and more have engaged in share repurchases, illustrating their dedication to building a loyal investor base.

The Chinese New Year holiday witnessed several noteworthy events in the pharmaceutical investment landscape. The opening of independent pricing for innovative drugs brings positive prospects for the Chinese pharmaceutical industry. Meanwhile, the Pharmaron Group experienced stock price declines due to weakened investor confidence and industry uncertainties. On the other hand, pharmaceutical companies actively repurchasing their shares aim to cultivate loyal long-term investors. As the industry moves forward, maintaining a rational and forward-thinking perspective will be crucial for pharmaceutical investors seeking to capitalize on emerging opportunities in this ever-evolving landscape.